Despite these strenuous efforts, only two of these cytokines have been approved by the FDA, IFN-α for the treatment of hairy cell leukemia since 1986 or as adjuvant treatment for melanoma, and IL-2 for the treatment of metastatic renal cancer and advanced melanoma since 1992 and 1998, respectively [14]. Here, IL2 is linked to melanoma.